NeuroMetrix (NASDAQ:NURO) Stock Price Crosses Above 200 Day Moving Average – Time to Sell?

NeuroMetrix, Inc. (NASDAQ:NURO) passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $4.35 and traded as high as $4.69. NeuroMetrix shares last traded at $4.55, with a volume of 35,522 shares.

Analyst Ratings Changes

Separately, Wall Street Zen began coverage on shares of NeuroMetrix in a report on Thursday, May 15th. They set a “sell” rating on the stock.

NeuroMetrix Trading Up 4.4%

The stock has a market capitalization of $9.37 million, a PE ratio of -0.99 and a beta of 1.82. The company’s 50-day moving average is $4.52 and its 200 day moving average is $4.35.

Hedge Funds Weigh In On NeuroMetrix

Several institutional investors have recently made changes to their positions in NURO. Deltec Asset Management LLC purchased a new stake in shares of NeuroMetrix in the first quarter valued at about $81,000. GTS Securities LLC purchased a new position in NeuroMetrix in the 4th quarter valued at $90,000. Finally, Renaissance Technologies LLC purchased a new position in NeuroMetrix in the 4th quarter valued at $46,000. 19.40% of the stock is owned by hedge funds and other institutional investors.

About NeuroMetrix

NeuroMetrix, Inc, a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use.